• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • Pay 2021 Membership Dues
  • Our Membership
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Find a Pediatric Dermatologist (from SPD)
        • Clinical Trials
        • Patient Advisory Committee
        • Learn more about PeDRA’s efforts to build capacity for patient engagement in pediatric dermatology research.

           

  • Education and Events
        • Virtual Education
        • PeDRA Podcasts
        • Mentorship Program
        • Early Career Support
        • 2021 PeDRA Annual Conference
        • Past PeDRA Conferences
        • Upcoming Events
        • Education and Events Archive
        • Save the Date!

          The 2021 PeDRA Annual Conference will take place October 14-16, 2021 in Bethesda, MD.

           

  • Research
        • Grants & Awards
        • Studies
        • Focused Study Groups
        • Publications
        • Clinical Trials
        • Spring Funding Opportunities

          2021 Research Fellowships
          due April 1
          2021 Childhood Eczema Challenge Grant
          due May 4

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • PeDRA is an independent 501(c)(3) nonprofit organization driven by the mission to create, inspire, and sustain research to prevent, treat, and cure childhood skin disease.

  • Member Login

Cutaneous Findings in Children Receiving MEK and BRAF Inhibitors

November 10, 2019 By Mike Siegel

Principal Investigator:

Christina Boull, MD
University of Minnesota

Overview:

This is a multi-center retrospective chart review of pediatric patients who have received MEK inhibitors and/or BRAF inhibitors to better document and describe the associated cutaneous changes. The use of targeted therapies in the MAP kinase pathway for cancer treatment is increasing and it is essential to anticipate and prevent associated skin toxicities to prevent interruption of these cancer therapies.

Status:

Analyzing data.

Participating Sites:

Filed Under: Active Studies, Skin Tumors and Reactions to Cancer Therapies

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2021 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy